World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
120
Citations
118484
World Ranking
3651
National Ranking
2016

Overview

David F. McDermott is affiliated with Beth Israel Deaconess Medical Center in the United States. Their research primarily focuses on oncology and related biomedical fields, with significant contributions in renal cell carcinoma treatment and cancer immunotherapy.

Their recent publications include:

  • Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma, 2020, Nature Medicine
  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial, 2020, ESMO Open
  • Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade, 2020, Cancer Cell
  • Progressive immune dysfunction with advancing disease stage in renal cell carcinoma, 2021, Cancer Cell
  • High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade, 2020, Nature Medicine

Their frequent co-authors include:

  • Toni K. Choueiri
  • Michael B. Atkins
  • Brian I. Rini
  • Sabina Signoretti
  • David A. Braun

They have published extensively in several venues, most notably:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal for ImmunoTherapy of Cancer
  • The Oncologist
  • Cancer Research

David F. McDermott's research largely spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology.

Within these broader fields, their work covers subfields such as:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Cancer Research
  • Molecular Biology
  • Surgery

The main topics of their studies are focused on:

  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Renal and related cancers
  • Pancreatic and Hepatic Oncology Research
  • Bladder and Urothelial Cancer Treatments
  • CAR-T cell therapy research

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George

  • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Roy S. Herbst;Jean Charles Soria;Marcin Kowanetz;Gregg D. Fine

  • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

    Gary Hudes;Michael Carducci;Piotr Tomczak;Janice Dutcher

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

    Michael A. Postow;Jason Chesney;Anna C. Pavlick;Caroline Robert

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  • Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Mark A. Warren

  • Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  • Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Bruce G. Redman

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

  • Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial

    Kim Margolin;Marc S Ernstoff;Omid Hamid;Donald Lawrence

  • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

    F Stephen Hodi;Jason Chesney;Anna C Pavlick;Caroline Robert

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion

    Arnold H. Zea;Paulo C. Rodriguez;Michael B. Atkins;Claudia Hernandez

  • Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

    David F. McDermott;Meredith M. Regan;Joseph I. Clark;Lawrence E. Flaherty

  • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Toni K Choueiri;Bernard Escudier;Thomas Powles;Nizar M Tannir

  • Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Osvaldo Arén Frontera

Frequent Co-Authors

Michael B. Atkins
Michael B. Atkins Georgetown University
Toni K. Choueiri
Toni K. Choueiri Harvard University
Sabina Signoretti
Sabina Signoretti Brigham and Women's Hospital
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
F. Stephen Hodi
F. Stephen Hodi Harvard University
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Elizabeth R. Plimack
Elizabeth R. Plimack Fox Chase Cancer Center
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Thomas Powles
Thomas Powles Queen Mary University of London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare pathways can open new doors for those interested in medicine but seeking flexible or accelerated options. For example, direct entry msn programs online allow individuals without a nursing background to quickly transition into advanced nursing roles. These programs are ideal for career changers who want to enter the healthcare field with minimal prerequisites.

If you're looking for accessible options, consider nursing schools with high acceptance rates. These programs often provide a more achievable entry point for aspiring nurses, supporting a diverse range of applicants.

Beyond clinical work, roles in healthcare administration are also in high demand. Those interested in the business and technology side of healthcare can explore the best online medical billing and coding schools, many of which offer financial aid and remote learning options.

Additionally, students seeking a smoother application process may want to look at nursing school without teas test demands. This can make the journey into nursing more accessible and less stressful.

Best Scientists Citing David F. McDermott

Trending Scientists